- Home
- DDOG vs MRNA Comparison
DDOG vs MRNA Comparison
Compare DDOG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDOG | MRNA |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.7B | 91.2B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DDOG | MRNA |
|---|---|---|
| Price | $175.41 | $241.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 47 | 23 |
| Target Price | ★ $295.55 | $138.37 |
| AVG Volume (30 Days) | 3.4M | ★ 16.3M |
| Earning Date | 11-04-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 0.59 | N/A |
| Revenue | $3,427,158,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $30.57 | $8.13 |
| Revenue Next Year | $22.69 | $16.26 |
| P/E Ratio | $698.96 | ★ N/A |
| Revenue Growth | ★ 27.68 | 4.29 |
| 52 Week Low | $98.01 | $22.28 |
| 52 Week High | $300.68 | $258.72 |
Technical Indicators
Market Signals| Indicator | DDOG | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 28.56 | 67.54 |
| Support Level | $104.32 | $45.39 |
| Resistance Level | $285.75 | N/A |
| Average True Range (ATR) | 16.12 | 22.88 |
| MACD | -9.15 | 0.23 |
| Stochastic Oscillator | 2.24 | 99.29 |
Price Performance
Historical ComparisonAbout DDOG Datadog Inc.
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, enables clients to monitor and analyze their entire information technology infrastructure, from servers to applications and Python scripts. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses to ensure uptime and latency objectives.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.